TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension

Background: Hypoparathyroidism (HP) is characterized by insufficient levels of parathyroid hormone (PTH), resulting in hypocalcemia, hyperphosphatemia, hypercalciuria, and a reduced quality of life (QoL). PTH replacement therapy should restore physiologic levels of PTH and restore downstream physiol...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Endocr Soc
Asıl Yazarlar: Rubin, Mishaela R, Rejnmark, Lars, Schwarz, Peter E, Vokes, Tamara J, Clarke, Bart, Ahmed, Intekhab, Hofbauer, Lorenz C, Palermo, Andrea, Marcocci, Claudio, Pagotto, Uberto, Eriksen, Erik F, Mourya, Sanchita, Markova, Denka, Pihl, Susanne, Shu, Aimee D, Khan, Aliya
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2021
Konular:
Bone and Mineral Metabolism
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090331/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.514
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller